# (53) K Breddin and CR Klimt (eds) (1981)

Second International Symposium on Clinical Trials held in Frankfurt am Main, West Germany from July 5-7, 1979 Controlled Clinical Trials: Design, Methods, and Analysis 1981: volume 1, issue 4, pages 281-443.

### Preamble

The First International Symposium on Clinical Trials mentioned in the Aims below does not appear to have been published.

#### Aims

This issue on Controlled Clinical Trials: Design, Methods, and Analysis is devoted to the Second International Symposium on Clinical Trials held in Frankfurt am Main, West Germany from July 5-7 1979, which followed the first one held in Lyon, Franc December 9-11, 1977. It was particularly appropriate to have such a symposium in Germany where as a result of the new drug law this technique of evaluating treatment in human beings has become of widespread interest. Those participants in the symposium who have voluntarily agreed to provide a manuscript are due our sincere gratitude since this was not a precondition for members of the Faculty of the symposium. The guest editors have attempted to bring those presentations which are of methodological interest. Our apologies are due to those who presented the findings of specific studies, which were not included in this issue because of the journal's editorial policy (Introduction, page 281).

## Contents (163 pages)

Introduction (K Breddin, Christian R Klimt) The conduct and principles of randomized clinical trials (Christian R Klimt) Randomized clinical trials: why not? (KK Überla) Organization of multicenter clinical trials (Curtis L Meinert) Patient recruitment techniques in clinical trials (Thaddeus E Prout) Terminating a long-term clinical trial (Christian R Klimt) Methods of quality control and of continuous audit procedures for controlled clinical trials (Genell L Knatterud) Controlled clinical trials: today's challenges for statisticians and designers (Jean-Pierre Boissel) Jerome Cornfield and the methodology of clinical trials (Paul Meier) Importance of prognostic factors in the analysis of data from clinical trials (Peter Armitage) Stratification in the design of a clinical trial (Paul Meier) Practical aspects of decision making in clinical trials: the Coronary Drug Project as a case study (The Coronary Drug Project Research Group) Problems of repeated significance testing (K Abt) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: some statistical aspects (JA Heady) Comparison of German and American law concerning clinical trials (Erwin Deutsch) Legal problems of controlled clinical trials (Horst Wilhelm Hasskarl) Role of an ethicist in the conduct of clinical trials in the United States (Michael P Hamilton) Role of ethical guidance committees in clinical research (H Breuer, FW Fischer) The ethics of informed consent (Thaddeus E Prout) Problems of informed consent for clinical trials in psychiatry (H Helmchen) Sponsors of the Second International Symposium on Long-Term Clinical Trials

#### Authors

The guest editors are K Breddin (no details provided) and Christian R Klimt MD, DrPH (President, Maryland Medical Research Institute, Baltimore, Maryland, USA). The authors are Professor Dr K Abt (Department of Biomathematics, Center of Medical Information, Medical School, University of Frankfurt, Federal Republic of Germany); Professor Peter Armitage (Department of Biomathematics, University of Oxford, Oxford, England); Jean-Pierre Boissel MD (Hôpital Cardio-Vasculaire et Pneumologique, Lyon, France); Professor H Breuer (Institut für Klinische Biochemie der Universitat Bonn, Bonn, Federal Republic of Germany); Professor Dr Erwin Deutsch (Professor of Law, University of Göttingen, Göttingen, Federal Republic of Germany); FW Fischer (Institut für Klinische Biochemie der Universitat Bonn, Bonn, Federal Republic of Germany); Canon Michael P Hamilton (Washington Cathedral, Mount Saint Alban, Washington, DC, USA); Dr Horst Wilhelm Hasskarl (Rechtsenwalt, Mutterstadt, Federal Republic of Germany) JA Heady (Department of Clinical Epidemiology and Social Medicine, Royal Free Hospital and University of London, London, England); Professor Dr H Helmchen (Direktor der Psychiatrischen Klinik der Freien Universität Berlin, Berlin, Federal Republic of Germany); Genell L Knatterud PhD (Division of Clinical Investigation, Maryland Medical Research Institute and Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, Maryland, USA); Paul Meier (Department of Statistics, University of Chicago, Chicago, Illinois, USA): Curtis L Meinert PhD (Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland, USA); Thaddeus E Prout MD (Chief of Medicine, Greater Baltimore Medical Center and The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA): The Coronary Drug Project Research Group (represented by Dr Paul L Canner; University of Maryland, Department of Epidemiology and Preventive Medicine, Division of Clinical Investigation, Baltimore, MD, USA); and, Professor, Dr med KK Überla (Institut fur Medizinische Informationsverarbitung, Statistik und Biomathematik, Munich, Federal Republic of Germany).